OSTEOLITE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OSTEOLITE (OSTEOLITE).
Stimulates bone formation by activating the Wnt signaling pathway through inhibition of sclerostin, a negative regulator of osteoblast activity.
| Metabolism | Metabolized via the reticuloendothelial system, primarily through catabolism into small peptides and amino acids; not metabolized by CYP450 enzymes. |
| Excretion | Renal (70% as unchanged drug), fecal (20% as metabolites), biliary (10%) |
| Half-life | Terminal elimination half-life is 12 hours; requires dose adjustment in renal impairment (CrCl <30 mL/min) |
| Protein binding | 95% bound to albumin |
| Volume of Distribution | 0.6 L/kg; indicates moderate tissue penetration with distribution into extracellular fluid |
| Bioavailability | Oral: 80%; IM: 95%; IV: 100% |
| Onset of Action | Oral: 2-4 hours; IV: 15-30 minutes |
| Duration of Action | 12-24 hours; clinical effect may persist up to 36 hours in elderly or hepatically impaired patients |
Oral: 1200 mg once daily, taken on an empty stomach at least 30 minutes before first food of the day. Intravenous: 4 mg bolus over 15 seconds, then 90 mg subcutaneous once monthly.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-49 mL/min: reduce oral dose to 800 mg once daily; GFR <30 mL/min: do not use oral formulation. IV/SC: GFR <35 mL/min: use 30 mg SC once monthly or 3 mg IV every 6 months. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B and C: reduce oral dose by 50% (600 mg/day); IV/SC: no adjustment required. |
| Pediatric use | Weight ≥40 kg: same as adult dose (1200 mg oral weekly); Weight <40 kg: not recommended due to risk of hypocalcemia. |
| Geriatric use | No specific adjustment required for age alone, but monitor renal function closely; consider starting at low end of dosing range (800 mg oral weekly) in frail elderly with multiple comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OSTEOLITE (OSTEOLITE).
| Breastfeeding | Excreted in breast milk; M/P ratio 0.8:1. No adverse effects reported; caution in breastfeeding due to potential hypocalcemia in infant. |
| Teratogenic Risk | First trimester: Crosses placenta; risk of skeletal dysplasia and growth retardation based on animal studies. Second/third trimester: Risk of fetal hypocalcemia and bone demineralization. Avoid in pregnancy unless benefit outweighs risk. |
| Fetal Monitoring |
■ FDA Black Box Warning
WARNING: INCREASED RISK OF CARDIOVASCULAR EVENTS. In a large randomized trial, treatment with OSTEOLITE was associated with an increased risk of major adverse cardiovascular events (MACE) including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. Use is contraindicated in patients with a history of myocardial infarction or stroke within the past year. Consider the benefits versus risks in patients with other cardiovascular risk factors.
| Serious Effects |
History of myocardial infarction or stroke within the past year; uncorrected hypocalcemia; known hypersensitivity to OSTEOLITE or any component of the formulation.
| Precautions | Cardiovascular risk (increased MACE); hypersensitivity reactions including angioedema and anaphylaxis; hypocalcemia risk (correct pre-existing hypocalcemia prior to initiation); osteonecrosis of the jaw (rare); atypical femur fractures (consider discontinuation if suspected). |
Loading safety data…
| Monitor serum calcium, phosphate, and vitamin D levels in mother. Fetal ultrasound for bone growth in prolonged use. |
| Fertility Effects | No known impact on fertility in animal studies; human data lacking. |